Highlights of This Issue 2251

SMALL MOLECULE THERAPEUTICS

2253 The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean C. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, and Sheng-Bin Peng

2264 Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth


2276 Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor

Ziyan Y. Pessetto, Yan Ma, Jeff J. Hirst, Margaret von Mehren, Scott J. Weir, and Andrew K. Godwin

2288 Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer

Melissa A. Babcock, Sanjeev Shukla, Pingfu Fu, Edwin J. Vazquez, Michelle A. Puchowicz, Joseph P. Molter, Christine Z. Oak, Gregory T. MacLennan, Chris A. Flask, Daniel J. Lindner, Yvonne Parker, Firouz Daneshgari, and Sanjay Gupta

2303 The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth

Michael D. Arensman, Donatello Teleca, Anna R. Lay, Kathleen M. Kershaw, Nanping Wu, Timothy R. Donahue, and David W. Dawson

2315 BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD


2328 Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma

Raghavendra Gowda, Subba Rao V. Madhunapantula, Arati Sharma, Omer F. Kuzu, and Gavin P. Robertson

LARGE MOLECULE THERAPEUTICS

2341 Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang, and David M. Goldenberg

2352 Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer

Christopher L. Daige, Jason F. Wiggins, Leslie Priddy, Terri Nelligan-Davis, Jane Zhao, and David Brown

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2361 Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer


2372 Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1

Carolina Castillo, M. Luz Flores, Rafael Medina, Begoña Pérez-Valderrama, Francisco Romero, María Tortolero, Miguel A. Japón, and Carmen Sáez

2384 Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs

Laurence Booth, Jane L. Roberts, Nichola Cruickshanks, Steven Grant, Andrew Poklepovic, and Paul Dent

2399 Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells

Jessian L. Munoz, Vivian Rodriguez-Cruz, Steven J. Greco, Vipul Nagula, Kathleen W. Scotto, and Pranela Rameshwar
### MODELS AND TECHNOLOGIES

#### 2450
**An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis**
Jonathan W. Astin, Stephen M.P. Jamieson, Tiffany C.Y. Eng, Maria V. Flores, June P. Misa, Annie Chien, Kathryn E. Crosier, and Philip S. Crosier

#### 2463
**Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D**
Ningning He, Nayoung Kim, Mee Song, Choa Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyunga Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills, and Sukjoon Yoon

---

### ABOUT THE COVER

Zebrafish embryos can be used to examine mechanisms of vascular development and as a platform with which to identify novel antivascular agents; this is an image of a 2-day-old zebrafish embryo showing developing lymphatic vessels in green (lyve1:egfp) and endothelial cell nuclei in red (kdrl:nls:mcherry). This embryo was live imaged for a further 20 hours to identify novel inhibitors of lymphatic vessel growth and revealed that flunarizine, a calcium channel antagonist, was able specifically induce lymphatic endothelial cell death. For details, see the article by Astin and colleagues on page 2450.
Molecular Cancer Therapeutics

13 (10)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://mct.aacrjournals.org/content/13/10">http://mct.aacrjournals.org/content/13/10</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications</td>
</tr>
<tr>
<td>Subscriptions</td>
<td>Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications</td>
</tr>
<tr>
<td></td>
<td>Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>